First brain pacemaker against Parkinson's: hope for those affected in Würzburg!

First brain pacemaker against Parkinson's: hope for those affected in Würzburg!

In a significant advance in the treatment of Parkinson's, a team from Würzburg implanted a new type of brain pacemaker for the first time in Germany in mid-June 2025. The procedure affected a 69-year-old patient and marks a milestone in deep brain stimulation (DBS), which is considered a long-term effective therapy for advanced Parkinson's disease. This innovative electrode has 16 contacts, enabling more precise and customizable brain stimulation, which could significantly improve treatment options for those affected. Loud World The patient has already reported positive changes in his condition three weeks after the procedure.

Parkinson's is a common neurodegenerative disease that affects over 1.2 million people worldwide. The course of the disease is manifested, among other things, by symptoms such as delayed movements, tremors, muscle stiffness and balance problems. Deep brain stimulation can help alleviate these movement disorders by sending electrical impulses to specific brain regions. The exact mechanism for improving symptoms is not yet fully understood, but the positive response from patients gives hope for the success of this innovative method.

Technology in detail

The newly developed software, which allows treating doctors to adapt and simulate the stimulation based on the patients' individual brain images, represents a further advance in treatment. In addition to Parkinson's, DBS is also being examined for other psychiatric disorders, such as severe depression or obsessive-compulsive disorder. The Deep Brain Stimulation Working Group provides valuable information and promotes the exchange of treatment options for patients suffering from this disease and the relevant advantages and disadvantages, such as gesundheitsinformation.de emphasized.

A look back shows: bilateral DBS was first used in Germany in 1993, and since then several thousand patients have been treated with it worldwide. The electrical and neurochemical effects on specific target areas in the brain can significantly alleviate or even delay symptoms in the advanced stages of the disease and also in the early stages. As the Brain Foundation mentioned, DBS is not only limited to Parkinson's, but is also used for dystonia, essential tremor and in studies of other diseases such as Alzheimer's.

Future of therapy

However, the challenges of treatment are significant. DBS is symptomatic and cannot stop the progression of the disease. Regular checks are necessary to optimally adjust the stimulation. To determine whether DBS is appropriate for a patient, experts have developed the “5-2-1” rule, which provides a clear indication for treatment based on how often patients need oral levodopa medication and what symptoms they experience.

With current advances in DBS technology, the hope of improving quality of life and symptom control for Parkinson's patients is one step closer. The latest developments in particular show that research in this area remains very popular and that there are still many opportunities for better treatment of this challenging disease.